Contract win for new stroke study

RNS Number : 7921W

IXICO plc

28 April 2021

 

IXICO plc

("IXICO" or the "Company")

Contract win for new stroke study

New therapeutic area, broadening IXICO's neurological footprint

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience , announces that it has executed a contract to provide neuroimaging services for a new clinical trial for acute ischemic stroke with its largest pharma client.

The contract win reflects a further broadening of IXICO's neurological footprint into a new therapeutic area with this client and demonstrates that the Company continues to build momentum in its growth strategy of further diversification into new therapeutic areas. Ischemic stroke is caused by a blockage cutting off the blood supply to the brain. This is the most common form of stroke and accounts for approximately 85% of cases. The new Phase II acute ischemic stroke trial, will be conducted across 50 sites in North America and Europe and is worth in excess of US$0.5m over 35 months.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "We are delighted to be awarded this new study by our existing pharma client. Having singularly focused on neurological disorders since our inception in 2004, IXICO has a long and established history of delivering advanced neuroimaging solutions to the biopharmaceutical sponsors. This new contract demonstrates our continually expanding footprint and deepening expertise within IXICO's proven specialist domain. "

For further information please contact:

IXICO plc			[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)				[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	[phone]
Paul McManus / Lianne Cawthorne /		[e-mail]
Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com   and follow us on Twitter @IxicoNews  

 

END

 

 

CNTSESESWEFSEDL